Tarsus Pharmaceuticals Inc.
01/17/2025 | Press release | Distributed by Public on 01/17/2025 16:09
Management Change/Compensation (Form 8-K)
Item 5.02. Departure of Directors or Certain Officers
On January 15, 2025, Rosemary Crane, a member of the Board of Directors (the "Board") of Tarsus Pharmaceuticals, Inc. (the "Company") notified the Company of her resignation as a member of the Board and any committees of the Board, effective January 17, 2025. The resignation is not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Effective January 17, 2025, the Company entered into a consulting agreement with Ms. Crane (the "Consulting Agreement") under which Ms. Crane will serve as a consultant to the Company. Ms. Crane will be eligible to continue to vest in her outstanding equity awards subject to her continuous service pursuant to the Consulting Agreement. The Consulting Agreement has an initial term of 6 months unless terminated earlier pursuant to its terms. The Consulting Agreement contains standard confidentiality, indemnification and intellectual property assignment provisions in favor of the Company.
Further, on January 16, 2025, based on the recommendation of the Board's Nominating and Corporate Governance Committee, the Board authorized and approved the appointment of Wendy Yarno, the Company's Lead Independent Director and current member of the Board, as Chairperson of the Commercial Committee of the Board, the transition of Ms. Yarno off the Audit Committee of the Board and the appointment of Andrew Goldberg, M.D., current member of the Board, as a member of the Audit Committee of the Board, each effective as of January 17, 2025.